Trending Articles

article thumbnail

Researchers grow 400+ brain cell types—a leap for Alzheimer’s and Parkinson’s research

Science Daily: Pharmacology News

Scientists at ETH Zurich have broken new ground by generating over 400 types of nerve cells from stem cells in the lab, far surpassing previous efforts that produced only a few dozen. By systematically experimenting with combinations of morphogens and gene regulators, the researchers replicated the vast diversity of neurons found in the human brain.

Research 259
article thumbnail

NGS is evolving: collaboration and tech lead the way

Drug Target Review

The next-generation sequencing (NGS) market is experiencing rapid growth, which is expected to continue for the foreseeable future. Research by Markets and Markets projects the market to grow from $12.13 billion in 2023 to about $23.55 billion by 2029, a compound annual growth rate (CAGR) of approximately 13.2 percent.​ 1 Emergen Research attributes this to the advantages of high-throughput sequencing technologies and declining sequencing costs​. 2 This trend reflects the increasing demand for g

RNA 91
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

In seconds, AI builds proteins to battle cancer and antibiotic resistance

Science Daily: Pharmacology News

Artificial intelligence is now designing custom proteins in seconds—a process that once took years—paving the way for cures to diseases like cancer and antibiotic-resistant infections. Australian scientists have joined this biomedical frontier by creating bacteria-killing proteins with AI. Their new platform, built by a team of biologists and computer scientists, is part of a global movement to democratize and accelerate protein design for medical breakthroughs.

Disease 275
article thumbnail

Actithera draws new investors to radiopharma drug pitch

BioPharma Drive: Drug Pricing

Skip to main content CONTINUE TO SITE ➞ Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy.

Drugs 151
article thumbnail

Bridging Innovation & Patient Care: The Growing Role of AI

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

article thumbnail

Rational Design of CDK12/13 and BRD4 Molecular Glue Degraders

Covalent Modifiers

Nathanael Schiander Gray , Zhe Zhuang , Woong Sub Byun , Zuzanna Kozicka , Katherine Donovan , Brendan Dwyer , Abby Thornhill , Hannah Jones , Zixuan Jiang , Xijun Zhu , Eric Fischer , Nicolas Thomä , Angew. Chem. Int. Ed. 2025 , e202508427. [link] Targeted protein degradation (TPD) is an emerging therapeutic approach for the selective elimination of disease-related proteins.

article thumbnail

Clinical Trial Efficiency: Best Practices in Clinical Trial Standardisation and Automation

Quanticate

In clinical trials we all want faster results and adaptability. These goals can be achieved with trial standardisation and automation. Both approaches aim to streamline processes, but they differ in focus, speed, and flexibility. Let’s explore the concept of standardising studies, its relationship with automation, and what each approach can offer.

More Trending

article thumbnail

CDD Vault Update (July 2025): Custom Axis Scaling, AUC Fold Change, Copy Reactions and Stoichiometry Tables, and Sample Tracking Improvements for the ELN

Collaborative Drug

CDD Vault Update (July 2025): Custom Axis Scaling, AUC Fold Change, Copy Reactions and Stoichiometry Tables, and Sample Tracking Improvements for the ELN

179
179
article thumbnail

What single cells are revealing about brain disorders

Drug Target Review

Neurological diseases are among the most complex and least understood conditions in medicine. Despite the knowledge that certain genes increase the risk of contracting diseases like Alzheimer’s and Parkinson’s, it is still not fully understood how those diseases develop in the brain. But that is beginning to change. At the centre of this shift is 10x Genomics – a company building tools that enable researchers to study individual cells and their gene activity, both in isolation and in their origi

article thumbnail

Structure‐Based Bioisosterism Design, Synthesis, Antitumor and Toxicity Assessment of Novel Aplysinopsin Analogs

Chemical Biology and Drug Design

Aplysinopsin analog 12g displayed moderate antiproliferative activity upon breast and cervical cancer cells, and in Zebrafish-based model showed the lethality rate of embryos and larvae, sublethal effects and significant inhibition of larvae growth in a period higher than cytotoxicity assay. In silico ADME analysis indicated 12g with good orally bioavailable.

Drugs 100
article thumbnail

This AI-powered lab runs itself—and discovers new materials 10x faster

Science Daily: Pharmacology News

A new leap in lab automation is shaking up how scientists discover materials. By switching from slow, traditional methods to real-time, dynamic chemical experiments, researchers have created a self-driving lab that collects 10 times more data, drastically accelerating progress. This new system not only saves time and resources but also paves the way for faster breakthroughs in clean energy, electronics, and sustainability—bringing us closer to a future where lab discoveries happen in days, not y

Research 253
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Renasant Bio, chasing drugs for ADPKD, raises $55M in seed funding

BioPharma Drive: Drug Pricing

The biotech is taking inspiration from cystic fibrosis treatment and applying a similar approach to developing "corrector" and "potentiator" medicines for the kidney disease.

Treatment 252
article thumbnail

Sunvozertinib

New Drug Approvals

Sunvozertinib CAS 2370013-12-8 DZD9008, 584.1 g/mol, C 29 H 35 ClFN 7 O 3 , A-1801, L1Q2K5JYO8 N -[5-[[4-[5-chloro-4-fluoro-2-(2-hydroxypropan-2-yl)anilino]pyrimidin-2-yl]amino]-2-[(3 R )-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl]prop-2-enamide FDA Zegfrovy, 7/2/2025 To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, with disease progression on or after platinum-based c

FDA 62
article thumbnail

Fixing drug discovery’s most persistent problem with AI

Drug Target Review

Before a compound can become a viable therapy, it must pass a series of tests – not just for potency, but for how it behaves in the body. Absorption, distribution, metabolism, excretion and toxicity – collectively known as ADMET – are among the most critical and challenging hurdles in small molecule drug discovery. Medicinal chemists often describe ADMET optimisation as a frustrating ‘whack-a-mole’ problem: improve one property and another tends to deteriorate.

article thumbnail

"Designer Drugs" in the 21st Century

Common Sense for Drug Policy Blog

"Designer Drugs" in the 21st Century "The term “designer drugs” was originally introduced to describe novel substances that are derived from clandestine alterations of well-known drugs of abuse, preserving or enhancing pharmacologic effects while remaining outside of legal control (Jerrard 1990 ). The term is currently applied more widely to include substances that originate from industrial or academic research but never receive medical approval.

Drugs 52
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

One shot, seven days: Long-acting levodopa gel tackles Parkinson’s tremors

Science Daily: Pharmacology News

Researchers in Australia have created a biodegradable gel that delivers Parkinson’s medications through a single weekly shot, replacing the need for multiple daily pills. Injected just under the skin, the gel steadily releases levodopa and carbidopa for seven days, helping keep tremors and stiffness in check while easing side effects linked to fluctuating doses.

Research 217
article thumbnail

AstraZeneca blood pressure drug succeeds in late-stage trial

BioPharma Drive: Drug Pricing

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose hypertension is either uncontrolled by or resistant to existing medicines.

Trials 221
article thumbnail

Risevistinel

New Drug Approvals

Risevistinel NYX-783 CAS 2591344-26-0 , UNII-52TU5MZG22 NYX 2925, 2012536-16-0, X062KF5ZV3 C 14 H 23 N 3 O 4 , 297.35 UNII-52TU5MZG22, X062KF5ZV3 (αS,4R)-α-[(1R)-1-Hydroxyethyl]-5-(2-methyl-1-oxopropyl)-1-oxo-2,5-diazaspiro[3.4]octane-2-acetamide 2,5-Diazaspiro[3.4]octane-2-acetamide, α-[(1 R )-1-hydroxyethyl]-5-(2-methyl-1-oxopropyl)-1-oxo-, (α S ,4 S )- (2 S ,3 R )-3-hydroxy-2-[(4 S )-5-(2-methylpropanoyl)-3-oxo-2,5-diazaspiro[3.4]octan-2-yl]butanamide NYX-783, NYX 2925 CS-0113907 HY-135741 NY

Disease 57
article thumbnail

Fixing failed drugs: AI solutions for toxicity in drug discovery – part 1

Drug Target Review

The pharmaceutical industry faces a persistent challenge: despite significant investments in drug development, a substantial proportion of promising candidates fail due to unforeseen toxicity issues. In a recent conversation with Layla Hosseini-Gerami, Chief Data Science Officer and Co-founder of Ignota Labs , we explored this critical issue, considering how artificial intelligence (AI) and advanced data science approaches may provide solutions.

Drugs 64
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Challenges and Solutions to Drug-Drug Interactions for Clinical Development

DrugBank

Drug-drug interactions (DDI) are a significant concern in clinical trials, where the safe and effective administration of drugs to patients is crucial. These interactions can alter the pharmacological activity of one or more drugs, potentially leading to diminished therapeutic effects or unexpected toxic reactions. The complexity of pharmacokinetics and pharmacodynamics, coupled with the variability in patient populations, makes predicting and managing DDI a particularly challenging aspect of dr

article thumbnail

Scientists just found 200+ hidden proteins that may drive Alzheimer’s

Science Daily: Pharmacology News

A surprising new study has uncovered over 200 misfolded proteins in the brains of aging rats with cognitive decline, beyond the infamous amyloid and tau plaques long blamed for Alzheimer’s. These shape-shifting proteins don’t clump into visible plaques, making them harder to detect but potentially just as harmful. Scientists believe these “stealth” molecules could evade the brain’s cleanup systems and quietly impair memory and brain function.

Treatment 202
article thumbnail

Takeda to seek approval of new kind of narcolepsy drug after study data

BioPharma Drive: Drug Pricing

Skip to main content CONTINUE TO SITE ➞ Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy.

Drugs 184
article thumbnail

Rezatapopt

New Drug Approvals

Rezatapopt, PC 14586 CAS 2636846-41-6 Molecular Weight 545.57 Synonyms PC14586 Formula C 28 H 31 F 4 N 5 O 2 CAS No. 2636846-41-6 4-[3-[4-[[(3 S ,4 R )-3-fluoro-1-methylpiperidin-4-yl]amino]-1-(2,2,2-trifluoroethyl)indol-2-yl]prop-2-ynylamino]-3-methoxy- N -methylbenzamide 4-[3-[4-[[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino]-1-(2,2,2-trifluoroethyl)indol-2-yl]prop-2-ynylamino]-3-methoxy-N-methylbenzamide Benzamide, 4-[[3-[4-[[(3S,4R)-3-fluoro-1-methyl-4-piperidinyl]amino]-1-(2,2,2-trifluoroe

article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

How Causal Inference is Transforming Real-World Observational Prospective Trials

Quanticate

Learn how causal inference methods improve real-world observational trials by reducing bias, enhancing validity, and informing decisions.

Trials 52
article thumbnail

Altasciences at ASGCT 2025: An Open Forum for All Things Gene and Cell Therapy | By Kaylyn Koenig

Alta Sciences

Altasciences at ASGCT 2025: An Open Forum for All Things Gene and Cell Therapy | By Kaylyn Koenig aasimakopoulos Thu, 07/10/2025 - 08:00 I recently returned from attending the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. This was my first conference since joining Altasciences, and I was excited to attend with some of my esteemed colleagues, Nobert Makori (Vice President of Toxicology), Steve Mason (Co-COO), and members of the Business Development team, Derek Storey, Gretchen

article thumbnail

Your Brain’s Hidden Defenses Against Alzheimer’s

Science Daily: Pharmacology News

Scientists at UCSF combined advanced brain-network modeling, genetics, and imaging to reveal how tau protein travels through neural highways and how certain genes either accelerate its toxic journey or shield brain regions from damage. Their extended Network Diffusion Model pinpoints four gene categories that govern vulnerability or resilience, reshaping our view of Alzheimer’s progression and spotlighting fresh therapeutic targets.

article thumbnail

The Redevelopment of ChEBI

The ChEMBL-og

We are delighted to announce that ChEBI’s beta version is now out and can be accessed at: [link] As many of you know, ChEBI is a widely used database and ontology of chemical entities of biological interest. It has a growing user base numbered in the hundreds of thousands and with millions of accesses each year. ChEBI has for the past >20 years provided the biological community with access to definitive small molecule information and data, including accurate representations of often complex c

article thumbnail

FDA, in policy shift, publishes some drug rejection letters

BioPharma Drive: Drug Pricing

The agency disclosed a tranche of more than 200 complete response letters from the past five years, but only those involving medicines that it later cleared.

FDA 167
article thumbnail

Gross-to-Net Bubble Hits $356B in 2024—But Growth Slows to 10-Year Low

Drug Channels

Is the gross-to-net bubble —the ever-widening gap between brand-name drug sales at list prices and their net revenues after rebates and discounts—finally beginning to deflate? Drug Channels Institute (DCI) estimates that the gross-to-net reductions for all brand-name drugs reached $356 billion in 2024, a 7% increase over the previous year. Yet despite this record total, the bubble expanded at the slowest rate in at least a decade.

article thumbnail

Generative AI Can Design Drugs. But Can It Own Them?

Drug Patent Watch

"The Future of Pharma is in Flux: Can AI-Designed Medicines Be Owned? As the pharmaceutical industry grapples with the rise of generative AI, a new question is emerging: who owns the rights to medicines designed by machines? In a groundbreaking development, researchers have successfully used AI to design novel compounds with unprecedented efficacy.

article thumbnail

Can zebrafish help humans regrow hearing cells?

Science Daily: Pharmacology News

Zebrafish can regenerate sensory hair cells that humans permanently lose, like those in the inner ear linked to hearing and balance. New research reveals two specific genes that control how different supporting cells in zebrafish divide and regenerate, offering clues to how mammals might someday tap into similar regenerative powers.

Research 168
article thumbnail

GLP-1 Drugs Increase Risk Of Acid Reflux, GERD

Drugs.com

TUESDAY, July 15, 2025 — Folks using GLP-1 weight loss drugs like Ozempic are more likely to suffer from severe acid reflux, a new study says. People with type 2 diabetes were more likely to suffer from gastroesophageal reflux disease (GERD).

Drugs 288
article thumbnail

Resigratinib

New Drug Approvals

Resigratinib, KIN 3248 CAS 2750709-91-0 C 26 H 27 F 2 N 7 O 3 523.5 g/mol 3-[2-(1-cyclopropyl-4,6-difluorobenzimidazol-5-yl)ethynyl]-1-[(3 S ,5 R )-5-(methoxymethyl)-1-prop-2-enoylpyrrolidin-3-yl]-5-(methylamino)pyrazole-4-carboxamide 3-[2-(1-Cyclopropyl-4,6-difluoro-1H-benzimidazol-5-yl)ethynyl]-1-[(3S,5R)-5-(methoxymethyl)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl]-5-(methylamino)-1H-pyrazole-4-carboxamide 3-[2-(1-cyclopropyl-4,6-difluorobenzimidazol-5-yl)ethynyl]-1-[(3S,5R)-5-(methoxymethyl)-1-p